文献速递母胎医学产科

胎儿开放性神经管缺陷宫内修复前染色体微阵列分析的意义

Implication of chromosomal microarray analysis prior to in-utero repair of fetal open neural tube defect.
PubMed 文献 · Ultrasound Obstet Gynecol · 2023-01-01

本研究为单中心回顾性队列,2011年9月至2021年7月共146例开放性神经管缺陷胎儿接受宫内修复,其中77例(52.7%)行染色体微阵列分析(CMA),65例(84%)结果正常,12例(16%)检出可报告拷贝数变异(CNV),其中2例为致病性。两组手术特征、并发症及母婴结局无显著差异,作者认为CMA应作为产前检测项目,但可报告CNV不应预先影响宫内修复资格,显著CMA结果需多学科个案讨论。

要点

  • 开放性神经管缺陷胎儿宫内修复前应提供CMA检测以助预后和复发风险咨询。
  • 可报告CNV组与CMA正常组的妊娠结局及运动功能无显著差异。
  • 显著CMA结果需多学科个案讨论评估宫内修复资格。

核心结论

  • 产前检出开放性神经管缺陷时应提供CMA标准诊断检测,因其对预后和复发风险咨询有影响。
  • 存在临床可报告CNV不应预先影响宫内修复资格,因这些病例的总体妊娠结局与CMA正常者相似。
  • 显著CMA结果需多学科个案讨论评估资格。
  • 为推广此单中心结论,应考虑开展更大规模的多中心长期研究。

研究设计与样本

  • 单中心回顾性队列研究,纳入2011年9月至2021年7月间接受腹腔镜辅助胎儿镜修复或开放式子宫切开胎儿手术的开放性神经管缺陷妊娠。
  • 所有患者符合MOMS资格标准且核型正常,其中77例同时行CMA检测。
  • 根据是否检出临床可报告CNV分为可报告CNV组和CMA正常组,比较手术特征、并发症及母婴结局。

主要发现

  • 研究期间146例开放性神经管缺陷胎儿符合条件并接受宫内修复,77例(52.7%)有CMA结果。
  • 65例(84%)CMA正常,12例(16%)检出可报告CNV,其中2例为致病性。
  • 第一例致病性CNV为749-kb的22q11.21中央区缺失,累及染色体22低拷贝重复区域B-D;第二例为1q21.1q21.2间1.3-Mb间质缺失。
  • 两组母亲人口学、临床特征、手术数据和术后并发症相似,分娩孕周及任何产科和早期新生儿结局无显著差异。
  • 两组出生时和12月龄运动功能及30月龄行走状态相似。

临床怎么用

  • 作者认为产前检出开放性神经管缺陷时应提供CMA标准诊断检测。
  • 作者认为存在临床可报告CNV不应预先影响宫内修复资格。
  • 作者认为显著CMA结果需多学科个案讨论评估资格。
  • 作者建议考虑开展更大规模的多中心长期研究以推广结论。

局限性

  • 原文指出为单中心系列,为推广结论应考虑开展更大规模的多中心长期研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: In-utero repair of open neural tube defects (ONTD) is an accepted treatment option with demonstrated superior outcome for eligible patients. While current guidelines recommend genetic testing by chromosomal microarray analysis (CMA) when a major congenital anomaly is detected prenatally, the requirement for an in-utero repair, based on the Management of Myelomeningocele Study (MOMS) criteria, is a normal karyotype. In this study, we aimed to evaluate if CMA should be recommended as a prerequisite for in-utero ONTD repair. METHODS: This was a retrospective cohort study of pregnancies complicated by ONTD that underwent laparotomy-assisted fetoscopic repair or open-hysterotomy fetal surgery at a single tertiary center between September 2011 and July 2021. All patients met the MOMS eligibility criteria and had a normal karyotype. In a subset of the pregnancies (n = 77), CMA testing was also conducted. We reviewed the CMA results and divided the cohort into two groups according to whether clinically reportable copy-number variants (CNV) were detected (reportable-CNV group) or not (normal-CMA group). Surgical characteristics, complications, and maternal and early neonatal outcomes were compared between the two groups. The primary outcomes were fetal or neonatal death, hydrocephalus, motor function at 12 months of age and walking status at 30 months of age. Standard parametric and non-parametric statistical tests were employed as appropriate. RESULTS: During the study period, 146 fetuses with ONTD were eligible for and underwent in-utero repair. CMA results were available for 77 (52.7%) patients. Of those, 65 (84%) had a normal CMA and 12 (16%) had a reportable CNV, two of which were classified as pathogenic. The first case with a pathogenic CNV was diagnosed with a 749-kb central 22q11.21 deletion spanning low-copy-repeat regions B-D of chromosome 22; the second case was diagnosed with a 1.3-Mb interstitial deletion at 1q21.1q21.2. Maternal demographics, clinical characteristics, operative data and postoperative complications were similar between those with normal CMA results and those with reportable CNVs. There were no significant differences in gestational age at delivery or any obstetric and early neonatal outcome between the study groups. Motor function at birth and at 12 months of age, and walking status at 30 months of age, were similar between the two groups. CONCLUSIONS: Standard diagnostic testing with CMA should be offered when an ONTD is detected prenatally, as this approach has implications for counseling regarding prognosis and recurrence risk. Our results indicate that the presence of a clinically reportable CNV should not a priori affect eligibility for in-utero repair, as overall pregnancy outcome is similar in these cases to that of cases with normal CMA. Nevertheless, significant CMA results will require a case-by-case multidisciplinary discussion to evaluate eligibility. To generalize the conclusion of this single-center series, a larger, multicenter long-term study should be considered. © 2023 International Society of Ultrasound in Obstetrics and Gynecology.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Zemet R, Krispin E, Johnson RM, et al. Implication of chromosomal microarray analysis prior to in-utero repair of fetal open neural tube defect. Ultrasound Obstet Gynecol. 2023. PMID: 36610024. doi:10.1002/uog.26152

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。